Canada · Delayed Price · Currency is CAD Pharmala Biotech Holdings Statistics
Total Valuation
CSE:MDMA has a market cap or net worth of CAD 13.58 million. The enterprise value is 12.33 million.
| Market Cap | 13.58M |
| Enterprise Value | 12.33M |
Important Dates
The next estimated earnings date is Friday, December 19, 2025.
| Earnings Date | Dec 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:MDMA has 108.62 million shares outstanding. The number of shares has increased by 11.19% in one year.
| Current Share Class | 108.62M |
| Shares Outstanding | 108.62M |
| Shares Change (YoY) | +11.19% |
| Shares Change (QoQ) | +3.47% |
| Owned by Insiders (%) | 9.29% |
| Owned by Institutions (%) | n/a |
| Float | 98.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.26 |
| PB Ratio | 4.93 |
| P/TBV Ratio | 14.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.05 |
| EV / Sales | 29.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.10
| Current Ratio | 2.10 |
| Quick Ratio | 1.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.96% and return on invested capital (ROIC) is -49.69%.
| Return on Equity (ROE) | -85.96% |
| Return on Assets (ROA) | -36.24% |
| Return on Invested Capital (ROIC) | -49.69% |
| Return on Capital Employed (ROCE) | -68.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.11% in the last 52 weeks. The beta is 0.90, so CSE:MDMA's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -42.11% |
| 50-Day Moving Average | 0.12 |
| 200-Day Moving Average | 0.15 |
| Relative Strength Index (RSI) | 47.30 |
| Average Volume (20 Days) | 278,041 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CSE:MDMA had revenue of CAD 420,810 and -2.04 million in losses. Loss per share was -0.02.
| Revenue | 420,810 |
| Gross Profit | 550,793 |
| Operating Income | -1.89M |
| Pretax Income | -2.04M |
| Net Income | -2.04M |
| EBITDA | -1.89M |
| EBIT | -1.89M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 1.25 million in cash and n/a in debt, giving a net cash position of 1.25 million or 0.01 per share.
| Cash & Cash Equivalents | 1.25M |
| Total Debt | n/a |
| Net Cash | 1.25M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 2.76M |
| Book Value Per Share | 0.03 |
| Working Capital | 959,927 |
Cash Flow
| Operating Cash Flow | -752,735 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 130.89% |
| Operating Margin | -448.06% |
| Pretax Margin | -484.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:MDMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.19% |
| Shareholder Yield | n/a |
| Earnings Yield | -15.01% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CSE:MDMA has an Altman Z-Score of 7.61 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.61 |
| Piotroski F-Score | 3 |